Affordable Access

Access to the full text

Clinical results for tocilizumab over one year in the clinical setting as assessed by CDAI (clinical disease activity index): CRP at week 12 and MMP-3 at week 24 are predictive factors for CDAI

Authors
  • Kaneko, Atsushi1
  • Kida, Daihei1
  • Saito, Kiwamu2
  • Tsukamoto, Masami3
  • Sato, Tomotaro1
  • 1 Nagoya Medical Center, National Hospital Organization, Department of Orthopedic Surgery and Rheumatology, 4-1-1 Sannomaru, Naka-ku, Nagoya, Aichi, Nagoya, 460-0001, Japan , Nagoya (Japan)
  • 2 Saito Clinic Orthopedic and Rheumatology, 1-10 Heiwagaoka, Meito-ku, Nagoya, Aichi, Nagoya, 465-0097, Japan , Nagoya (Japan)
  • 3 Asahigaoka Orthopedics, Nagoya, Japan , Nagoya (Japan)
Type
Published Article
Journal
Rheumatology International
Publisher
Springer-Verlag
Publication Date
Nov 30, 2011
Volume
32
Issue
11
Pages
3631–3637
Identifiers
DOI: 10.1007/s00296-011-2256-5
Source
Springer Nature
Keywords
License
Yellow

Abstract

To investigate the clinical results of 1 year tocilizumab (TCZ) treatment of rheumatoid arthritis patients in clinical practice by using the clinical disease activity index (CDAI). Thirty-one patients with inadequate response to DMARDs, including methotrexate (MTX), or TNF inhibitors received TCZ (8 mg every 4 weeks). The clinical responses were measured using the 28-joint disease activity score (DAS28-ESR) and CDAI. Matrix metalloproteinase-3 (MMP-3) was assessed as a serological biomarker. Mean baseline DAS28-ESR was 5.96, decreasing to 2.89 at week 52 with a remission rate (DAS28-ESR < 2.6) of 35.5%. Mean baseline CDAI was 28.4, decreasing to 10.2 at week 52 with a remission rate (CDAI ≤ 2.8) of 22.6%. Of patients whose CRP levels had fallen to below the limit of detection by week 12, 65.2% achieved remission or low disease activity as assessed by CDAI at week 52. Median baseline MMP-3 level was 165.7 ng/mL, decreasing to 79.5 ng/mL at week 52. A positive correlation was seen between CDAI at week 52 and MMP-3 level from week 12 onward. About 50% of the patients treated with TCZ in clinical practice achieved a low disease activity level at week 52 as assessed by CDAI, which does not include acute-phase proteins. Our results suggested that CRP levels falling to below the limit of detection by week 12 and MMP-3 ≤ 80.6 ng/mL at week 24 could predict low disease activity or remission at week 52 as assessed by CDAI.

Report this publication

Statistics

Seen <100 times